Company: GLPG
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001558370-25-003806
Chunk: 422

Company: GALAPAGOS NV
Filing Date: 2025-03-27
Form: 20-F
Item: Item 19
Chunk 422
---
 ​    
Effect of exchange rate differences on cash and cash equivalents                         ​   ​          1,782   ​    ​        (1,522)   ​    ​         22,293   ​   ​    
​                                                                                        ​   ​              ​   ​    ​              ​   ​    ​              ​   ​   ​    
Cash and cash equivalents at end of year                                                 ​   €         64,239   ​    €        166,810   ​    €        508,117   ​   22   
​
The accompanying notes form an integral part of these financial statements. 
​
​
​

F-10

Notes to Consolidated Financial Statements1. General informationGalapagos NV is a limited liability company incorporated in Belgium and has its registered office at Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium. In the notes to the consolidated financial statements, references to “we,” “us,” “the group” or “Galapagos” include Galapagos NV together with its subsidiaries. We refer to note 34 for a list of consolidated companies.We are a global biotechnology company with operations in Europe and the US dedicated to developing medicines focusing on oncology and immunology.The components of the result presented in the financial statements include the results of the companies mentioned in note 34 Consolidated companies as of December 31, 2024. Our operations had 704 employees on December 31, 2024 (as compared to 1,123 employees on December 31, 2023, of which 646 employees working in our continuing operations) mainly working in our operating facilities in Mechelen (the Belgian headquarters), the Netherlands, France, Switzerland, and the United States.On January 31, 2024 we announced that we successfully completed the transfer of the Jyseleca® business to Alfasigma, including the European and UK Marketing Authorizations, the commercial, medical and development activities for Jyseleca® and approximately 400 positions in 14 European countries. The transfer of our Jyseleca® business has been determined to meet the criteria to be classified as held for sale and discontinued operations in our financial statements for the year ended December 31, 2023. We also presented all income statement items fully related to the transferred Jyseleca® business on a separate line “Net profit/loss (-) from discontinued operations, net of tax” in our consolidated income statement.We refer to